DUBLIN--(BUSINESS WIRE)--The "Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.
This latest pipeline guide provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
- Merck & Co Inc
- Mereo Biopharma Group Plc
- Repros Therapeutics Inc
Key Topics Covered
- Report Coverage
- Secondary (Hypogonadotropic) Hypogonadism - Overview
- Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
- Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles
For more information about this report visit https://www.researchandmarkets.com/research/gdj5v7/secondary?w=4